Absci/$ABSI
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Absci
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
Ticker
$ABSI
Sector
Primary listing
Employees
157
Headquarters
Website
Absci Metrics
BasicAdvanced
$499M
-
-$0.94
2.02
-
Price and volume
Market cap
$499M
Beta
2.02
52-week high
$6.33
52-week low
$2.01
Average daily volume
5.9M
Financial strength
Current ratio
4.387
Quick ratio
3.772
Long term debt to equity
2.142
Total debt to equity
4.275
Interest coverage (TTM)
-311.21%
Profitability
EBITDA (TTM)
-103.73
Gross margin (TTM)
-1,634.75%
Net profit margin (TTM)
-2,737.94%
Operating margin (TTM)
-2,812.74%
Effective tax rate (TTM)
-0.16%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-31.26%
Return on equity (TTM)
-57.39%
Valuation
Price to revenue (TTM)
96.858
Price to book
2.46
Price to tangible book (TTM)
3.27
Price to free cash flow (TTM)
-5.224
Free cash flow yield (TTM)
-19.14%
Free cash flow per share (TTM)
-0.638
Growth
Revenue change (TTM)
27.32%
Earnings per share change (TTM)
1.45%
3-year revenue growth (CAGR)
-4.91%
3-year earnings per share growth (CAGR)
-8.83%
What the Analysts think about Absci
Analyst ratings (Buy, Hold, Sell) for Absci stock.
Bulls say / Bears say
In July 2025, Absci successfully raised gross proceeds of around $50 million through an underwritten public offering and secured an additional $14 million via its at-the-market facility, strengthening its cash position and extending its operating runway into the first half of 2028 (NASDAQ Aug 07, 2025).
Absci broadened its AI Drug Creation partnership with Almirall by targeting a second dermatology indication, making it eligible for up to roughly $650 million in upfront, research and development, and post-approval milestone payments, plus royalties. This demonstrates the strength and scalability of its platform (NASDAQ Aug 07, 2025).
The company expects an interim Phase 1 readout for its lead program ABS-101 (anti-TL1A) later this year, representing a key clinical milestone that could reduce risk in the pipeline and draw additional partnership interest (NASDAQ Aug 07, 2025).
Absci’s Q1 2025 revenue was $1.18 million, falling short of the Zacks Consensus Estimate by 43.86% and reflecting persistent volatility and challenges in generating consistent top-line growth (Zacks May 13, 2025).
In Q2 2025, Absci posted GAAP revenue of only $0.6 million—a 54% year-over-year drop—and missed consensus revenue estimates by over 50%, illustrating the unpredictable nature of its milestone-based partnerships (Motley Fool Aug 12, 2025).
The company raised about $50 million in an underwritten offering plus another $14 million via its at-the-market facility in July 2025, signaling ongoing reliance on dilutive equity financing to continue operating, which could dilute existing shareholder value (NASDAQ Aug 07, 2025).
Data summarised monthly by Lightyear AI. Last updated on 8 Nov 2025.
Absci Financial Performance
Revenues and expenses
Absci Earnings Performance
Company profitability
Absci News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Absci stock?
Absci (ABSI) has a market cap of $499M as of November 08, 2025.
What is the P/E ratio for Absci stock?
The price to earnings (P/E) ratio for Absci (ABSI) stock is 0 as of November 08, 2025.
Does Absci stock pay dividends?
No, Absci (ABSI) stock does not pay dividends to its shareholders as of November 08, 2025.
When is the next Absci dividend payment date?
Absci (ABSI) stock does not pay dividends to its shareholders.
What is the beta indicator for Absci?
Absci (ABSI) has a beta rating of 2.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.